Reid Hoffman: Doctors Who Skip AI Second Opinions Are 'Bordering on Malpractice'

At WIRED Health in London on April 16, LinkedIn cofounder Reid Hoffman declared that physicians who skip AI second opinions are “bordering on committing malpractice.” The statement, reported by WIRED, frames a live debate: whether frontier AI models are reliable enough to become routine tools in clinical decision-making.

The Malpractice Threshold

Hoffman’s position is not that doctors should defer to AI — it’s that they should interrogate it. “You could very well go, ‘No, I think you’re wrong, I think it’s this,’” he told the WIRED Health audience. His core argument is epistemic breadth: frontier models from companies like OpenAI and Anthropic have “ingested trillion-plus words of information,” functioning as a literature synthesizer no individual clinician can match. He applies this standard to himself, using frontier models for his own health decisions and requiring his personal concierge doctors to do the same.

A Contested Evidence Base

That framing collides with recent research. A major study published earlier in 2026 found that large language models pose real risks to members of the public seeking medical guidance, specifically citing inaccurate and inconsistently reproducible outputs. The crucial distinction — expert-guided consultation versus unsupervised patient use — is one Hoffman’s malpractice framing tends to blur.

According to WIRED, Hoffman also sees AI triage as a structural remedy for capacity-strained systems. Citing the UK’s National Health Service — burdened by GP shortages and expanding waiting lists — he envisions a freely accessible AI medical assistant on every smartphone, handling early triage before any in-person appointment.

Drug Discovery and Conflict of Interest

Hoffman cofounded cancer drug-discovery startup Manas AI alongside its CEO, oncologist Siddhartha Mukherjee, with an ambition to compress the decade-long drug-development cycle to just a few years. That commercial context is worth noting: his advocacy for faster FDA regulatory review and broader frontier-model adoption in medicine aligns directly with conditions that would benefit Manas AI’s core business.

Why This Matters

The malpractice provocation is deliberate — and effective at forcing a conversation the industry needs to have. The real question isn’t whether AI adds value in clinical settings (targeted diagnostic tools increasingly do) but whether frontier general-purpose models meet the evidentiary bar for clinical recommendation. Hoffman is arguing yes, loudly. Regulators and the medical community will set the actual standard.